CIBC Asset Management Inc decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 26.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,185 shares of the life sciences company's stock after selling 19,552 shares during the period. CIBC Asset Management Inc's holdings in Illumina were worth $7,197,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in ILMN. Versant Capital Management Inc lifted its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in Illumina during the 2nd quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new position in Illumina in the 2nd quarter worth about $63,000. 89.42% of the stock is owned by institutional investors.
Illumina Stock Performance
Shares of Illumina stock opened at $135.00 on Monday. The business has a 50-day simple moving average of $139.66 and a 200 day simple moving average of $124.31. The firm has a market capitalization of $21.41 billion, a price-to-earnings ratio of -13.56 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a one year low of $93.39 and a one year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the company posted $0.33 earnings per share. The company's quarterly revenue was down 3.5% on a year-over-year basis. On average, research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of recent research reports. Leerink Partners lifted their price target on Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Stephens lifted their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. TD Cowen boosted their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Barclays raised their price target on shares of Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $164.00.
Read Our Latest Research Report on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
